WHO using ring vaccine approach against Ebola

After three weeks with no new cases of ebola being reported in Sierra Leone, a new case was detected late last week in Kambia, spurring the use of the first "ring vaccination" of an experimental Ebola drug in the country.

Ring vaccination involves vaccinating anyone who came into contact with an infected patient, plus the contacts of contacts. The experimental drug being used is  a VSV-EBOV vaccine currently in a Phase 3 efficacy trial. 

A team  from Conakry, Guinea joined a World Health Organization and Sierra Leone Ministry of Health team in Kambia to track the transmission source and locate anyone who may have come in contact with the infected patient. They were joined by another team from Freetown, South Africa.

“Although no-one wanted to see more cases of Ebola virus disease in Sierra Leone, we kept all our teams on alert and ready to respond and close down any new transmission,” Dr. Anders Nordstrom, WHO representative in Sierra Leone, said.

The vaccine trial is funded by WHO, with support from the Wellcome Trust, the United Kingdom Department for International Development, the Norwegian Ministry of Foreign Affairs to the Norwegian Institute of Public Health through the Research Council of Norway, the Canadian government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development, and MSF.

Organizations in this Story

World Health Organization

Want to get notified whenever we write about World Health Organization ?
Next time we write about World Health Organization, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.